US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

17.79

+0.19001.08%

Post-market: 17.790.00000.00%16:20 EDT

Volume:841.25K

Turnover:14.89M

Market Cap:1.07B

PE:-5.92

High:17.95

Open:17.60

Low:17.06

Close:17.60

Loading ...

Overview Company News Filings

IBM rolls out new chips and servers, aims for simplified AI

Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)

Evercore ISI Sticks to Their Buy Rating for Spyre Therapeutics (SYRE)

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

U.S. RESEARCH ROUNDUP-American Airlines, Jabil, Lennar

Spyre Therapeutics Inc : Jefferies Raises Target Price to $47 From $43

THOMSON REUTERS

JonesTrading Keeps Their Hold Rating on Spyre Therapeutics (SYRE)

Spyre Therapeutics reports positive interim Phase 1 results for TL1A antibodies

Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases

Spyre Therapeutics Inc - Spy002 and Spy072 Well Tolerated, Support Quarterly Dosing

THOMSON REUTERS

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation Tl1a Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

THOMSON REUTERS

Spyre Therapeutics Inc. to Announce Results for the First Quarter 2025

Spyre Therapeutics Announces Inducement Stock Option Grants for New Employees Under 2018 Equity Plan

Spyre Therapeutics Inc. Convened Annual Stockholders Meeting

Spyre Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference

Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Spyre Therapeutics Inc: Expected Cash Runway Into Second Half of 2028

THOMSON REUTERS

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (Ddw) 2025 Including up to Eight Months of Follow-up From an Ongoing Phase 1 Trial of Spy001

THOMSON REUTERS

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Inc. Announces Inducement Awards Granting Stock Options to Non-Executive Employees Under 2018 Equity Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":17.79,"timestamp":1753473600000,"preClose":17.6,"halted":0,"volume":841250,"hourTrading":{"tag":"盘后","latestPrice":17.79,"preClose":17.79,"latestTime":"16:20 EDT","volume":10332,"amount":183805.86,"timestamp":1753474800512},"delay":0,"floatShares":46623089,"shares":60353561,"eps":-3.006383,"marketStatus":"Market Closed","change":0.19,"latestTime":"07-25 16:00:00 EDT","open":17.6,"high":17.95,"low":17.06,"amount":14890043.161582,"amplitude":0.050568,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.006383,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":17.6,"postHourTrading":{"tag":"盘后","latestPrice":17.79,"preClose":17.79,"latestTime":"16:20 EDT","volume":10332,"amount":183805.86,"timestamp":1753474800512},"volumeRatio":1.7656382550340075,"impliedVol":0.4913,"impliedVolPercentile":0.176},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":46623089,"roa":"-25.34%","roe":"-65.82%","lyrEps":-3.180151,"volumeRatio":1.7656382550340075,"shares":60353561,"dividePrice":0,"high":17.95,"amplitude":0.050568,"preClose":17.6,"low":17.06,"week52Low":10.91,"pbRate":"3.29","week52High":40.26,"institutionHeld":0,"latestPrice":17.79,"eps":-3.006383,"divideRate":0,"volume":841250,"delay":0,"ttmEps":-3.006383,"open":17.6,"prevYearClose":23.28,"prevWeekClose":16.29,"prevMonthClose":14.97,"prevQuarterClose":14.97,"fiveDayClose":16.29,"twentyDayClose":16.02,"sixtyDayClose":15.02},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2549546083","title":"IBM rolls out new chips and servers, aims for simplified AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2549546083","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549546083?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"IBM rolls out new chips and servers, aims for simplified AIBy Stephen Nellis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nL6N3T40QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","LU0640476718.USD","LU1861215975.USD","SYRE","LU1261432733.SGD","LU0106261372.USD","IE0004445015.USD","2NVD.UK","LU0029864427.USD","LU1852331112.SGD","NVD2.UK","LU1244550221.USD","LU1035775433.USD","IE00BJLML261.HKD","LU2403377893.USD","LU1244550494.USD","LU0175139822.USD","NVDS","IE00BJJMRY28.SGD","LU0082616367.USD","LU1116320737.USD","LU1712237335.SGD","NVD","SNVD.UK","LU2237957902.USD","3NVD.UK","NVIW.SI","NVD3.UK","NVDY","NVDU","LU1721428933.USD","NVDS.UK","SG9999015358.SGD","SGXZ23171101.USD","LU1868837300.USD","IBM","LU1935042488.USD","LU0689626769.HKD","LU1861220033.SGD","LU1242518931.SGD","NVDX","LU0057025933.USD","LU2360106780.USD","SG9999000418.SGD","NVDD","LU0345770993.USD"],"gpt_icon":1},{"id":"2545458505","title":"Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2545458505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545458505?lang=en_us&edition=fundamental","pubTime":"2025-06-23 01:00","pubTimestamp":1750611614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sandoz Group Ltd (SDZXF – Research Report) and Spyre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sandoz-group-ltd-othersdzxf-and-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sandoz-group-ltd-othersdzxf-and-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4137","SYRE","HCSG"],"gpt_icon":0},{"id":"2544113299","title":"Evercore ISI Sticks to Their Buy Rating for Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2544113299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544113299?lang=en_us&edition=fundamental","pubTime":"2025-06-19 13:56","pubTimestamp":1750312587,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) yesterday. The company’s shares closed yest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-their-buy-rating-for-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-their-buy-rating-for-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2544750069","title":"Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2544750069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544750069?lang=en_us&edition=fundamental","pubTime":"2025-06-18 18:20","pubTimestamp":1750242005,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE – Research Report) and Unit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-and-unitedhealth-unh-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-and-unitedhealth-unh-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211328371.USD","SG9999002232.USD","LU0820562030.AUD","LU0094547139.USD","IE00B2B36J28.USD","IE00B1BXHZ80.USD","IE00B7KXQ091.USD","LU1791710582.SGD","BK4534","LU2362540622.SGD","LU2552382215.SGD","LU0820561909.HKD","LU0048584097.USD","LU1674673428.USD","IE00BJJMRY28.SGD","LU0053666078.USD","LU0353189680.USD","LU0965509010.AUD","LU1064131342.USD","LU0496365809.HKD","LU2125154778.USD","LU0310800965.SGD","LU2279689827.SGD","LU1074936037.SGD","LU2491050154.USD","SYRE","LU1267930730.SGD","BK4566","LU0345770993.USD","UNH","LU0187121727.USD","LU0965509101.SGD","IE00B775H168.HKD","LU1069347547.HKD","HCSG","LU0058720904.USD","LU0354030438.USD","LU1267930490.SGD","LU0211326755.USD","LU0342679015.USD","LU1670627923.USD","LU0211326839.USD","LU1548497426.USD","LU1496350502.SGD","LU0198837287.USD","IE00B19Z3581.USD","LU2028103732.USD","LU2362541273.HKD","LU1066051811.HKD","LU0128525689.USD"],"gpt_icon":0},{"id":"2544926681","title":"U.S. RESEARCH ROUNDUP-American Airlines, Jabil, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2544926681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544926681?lang=en_us&edition=fundamental","pubTime":"2025-06-18 16:01","pubTimestamp":1750233710,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-American Airlines, Jabil, LennarJune 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nL4N3SL0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861215975.USD","LU2091194634.USD","JBL","SG9999018857.SGD","CAVA","SG9999014880.SGD","BK4500","LU1015430645.USD","SG9999014906.USD","LUV","BK4088","BK4585","LU0831103253.SGD","BK4539","LU0314104364.USD","GNW","BK4150","BK4550","LU0348735423.USD","SGXZ99366536.SGD","IE00BJT1NW94.SGD","LU1019632923.USD","LU1169589451.USD","LU1023061713.HKD","LU1051770623.HKD","HON","LU0264606111.USD","LU0417516738.SGD","UAL","AAL","IE0002141913.USD","LU1481107354.HKD","LU0149721374.USD","SGXZ31699556.SGD","BK4559","LEN","LU0572940350.SGD","LU1668664300.SGD","LU1814569148.SGD","SRPT","SYRE","SGXZ51526630.SGD","DAL","BK4588","HSBA.UK","BK4512","FLUT","LU2449936058.SGD","LU0307460666.USD"],"gpt_icon":1},{"id":"2544940140","title":"Spyre Therapeutics Inc : Jefferies Raises Target Price to $47 From $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2544940140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544940140?lang=en_us&edition=fundamental","pubTime":"2025-06-18 14:02","pubTimestamp":1750226579,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nFWN3SK1OD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2544119990","title":"JonesTrading Keeps Their Hold Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2544119990","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544119990?lang=en_us&edition=fundamental","pubTime":"2025-06-18 03:45","pubTimestamp":1750189511,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading maintained a Hold rating on Spyre Therapeutics (SYRE – Research Report). The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-hold-rating-on-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-hold-rating-on-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"JonesTrading Keeps Their Hold Rating on Spyre Therapeutics (SYRE)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2544577964","title":"Spyre Therapeutics reports positive interim Phase 1 results for TL1A antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2544577964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544577964?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:35","pubTimestamp":1750160134,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced positive interim Phase 1 results from its first-in-human trials of SPY002 and SPY072, two investigational, nove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-reports-positive-interim-phase-1-results-for-tl1a-antibodies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-reports-positive-interim-phase-1-results-for-tl1a-antibodies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","SYRE","BK4139","BK4007"],"gpt_icon":0},{"id":"2544096170","title":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2544096170","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544096170?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:30","pubTimestamp":1750159845,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases. Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL2NYgl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2544961728","title":"Spyre Therapeutics Inc - Spy002 and Spy072 Well Tolerated, Support Quarterly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2544961728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544961728?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:30","pubTimestamp":1750159804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA2ZGXM3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2544617409","title":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation Tl1a Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2544617409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544617409?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:30","pubTimestamp":1750159804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA2ZGXM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2544988315","title":"Spyre Therapeutics Inc. to Announce Results for the First Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2544988315","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544988315?lang=en_us&edition=fundamental","pubTime":"2025-06-17 04:05","pubTimestamp":1750104326,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on June 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL2Km46k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2541989088","title":"Spyre Therapeutics Announces Inducement Stock Option Grants for New Employees Under 2018 Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2541989088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541989088?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:05","pubTimestamp":1749240318,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc., a clinical-stage biotechnology company, announced on June 6, 2025, that its independent Compensation Committee has approved the grant of stock options to three non-executive employees. The inducement awards, granted under the company's 2018 Equity Inducement Plan, allow for the purchase of 50,200 shares of common stock at an exercise price of $15.40 per share, consistent with the closing price on June 2, 2025. These options come with a 10-year term and vest over a four-year period, beginning with one-fourth of the shares after the first year of employment, followed by monthly vesting of one-forty-eighth of the shares. These terms are contingent upon continuous service with Spyre.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL9M7CFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2540671803","title":"Spyre Therapeutics Inc. Convened Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540671803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540671803?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:02","pubTimestamp":1748894560,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. held its Annual Meeting of Stockholders on May 29, 2025. During the meeting, stockholders elected Peter Harwin, Michael Henderson, and Sandra Milligan as Class III directors. The stockholders also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL6FDdPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2538768664","title":"Spyre Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538768664","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538768664?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:30","pubTimestamp":1748435426,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. , a clinical-stage biotechnology company, is set to participate in the Jefferies Global Healthcare Conference on June 4, 2025. The company, known for its advancements in antibody engineering and therapeutic combinations for the treatment of Inflammatory Bowel Disease and other immune-mediated diseases, will have its management present at a fireside session scheduled for 8:10 am ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5Hfr2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2534913162","title":"Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534913162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534913162?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:55","pubTimestamp":1746737755,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummarySpyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 60 cents per share for the quarter ended Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG3HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2534648911","title":"Spyre Therapeutics Inc:  Expected Cash Runway Into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2534648911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534648911?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:33","pubTimestamp":1746736420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2533878586","title":"Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (Ddw) 2025 Including up to Eight Months of Follow-up From an Ongoing Phase 1 Trial of Spy001","url":"https://stock-news.laohu8.com/highlight/detail?id=2533878586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533878586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA51QP7W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2533586580","title":"Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586580","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586580?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease . SPY001 pharmacokinetic  data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab. SPY001 pharmacodynamic  data up to eight months showed that a single dose of SPY001 resulted in rapid and sustained saturation of α4β7 receptors at expected Phase 2 trough concentrations. Spyre presented results out to eight months of follow up from its SPY001 Phase 1 program.Updated results from our ongoing Phase 1 trial of SPY001, our novel half-life extended α4β7 antibody for the treatment of IBD, continues to show that SPY001 is well tolerated, has a half-life of more than three-fold compared to vedolizumab based on population PK modeling, and sustains target engagement at expected Phase 2 trough concentrations. This longer follow-up data strengthens the potential for SPY001 to demonstrate improved in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4007","PK","SYRE","LU1169590202.USD","LU1169589451.USD","BK4023","PD","LENZ","IBD","BK4218","BK4139"],"gpt_icon":0},{"id":"2532635871","title":"Spyre Therapeutics Inc. Announces Inducement Awards Granting Stock Options to Non-Executive Employees Under 2018 Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2532635871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532635871?lang=en_us&edition=fundamental","pubTime":"2025-05-03 04:05","pubTimestamp":1746216330,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 2, 2025 - Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced the approval of stock options as an equity inducement for seven non-executive employees. The company's independent Compensation Committee of the Board of Directors has granted options to purchase a total of 64,400 shares under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. Approved on May 1, 2025, the stock options have a 10-year term with an exercise price of $14.66, matching the closing price of Spyre's common stock on that date. The vesting schedule stipulates that one-fourth of the shares become exercisable on the first anniversary of the employee's start date, with the remainder vesting monthly over four years, contingent on continuous service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL10GsWv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86},{"market":"US","date":"2024-05-09","symbol":"SYRE","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.25,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":12,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-07-25","current":-5.084011,"percent":0.408759,"low":-10.261647,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"high":-0.199399,"avg":-5.057176,"sd":1.886399,"marketCap":1062222673},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673}],"updateTime":1753570711438}}}